RNLXD (Renalytix) Institutional Ownership: 0.01% (As of Aug. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RNLXD Renalytix PLC RNLXD
46 GF Score
Price $4.11
GF Value $5.55
! 3 Warning Signs
View Full Analysis

What is Renalytix Institutional Ownership?

Renalytix RNLXD +0.46% 46 Institutional Ownership is 0.01% as of Aug. 11, 2026. GuruFocus rates RNLXD with a GF Score™ of 46/100 and a GF Value™ of $5.55. The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Renalytix's institutional ownership is 0.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Renalytix's Insider Ownership is 13.55%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Renalytix's Float Percentage Of Total Shares Outstanding is 0.00%.

Renalytix Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Renalytix's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renalytix Institutional Ownership Chart

Renalytix Historical Data

The historical data trend for Renalytix can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 0.19 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17
RNLXD
46GF Score
Renalytix PLC RNLXD
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Renalytix Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.01% mean?
Renalytix (RNLXD) has a Institutional Ownership of 0.01% as of Aug. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Renalytix and its competitors.
Is Renalytix's Institutional Ownership too high?
Renalytix's current Institutional Ownership is 0.01%. Overall, Renalytix has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Renalytix's Institutional Ownership compare to VEEV and BTSG?
Renalytix's Institutional Ownership of 0.01% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Healthcare Providers & Services company?
A good Institutional Ownership depends on the Healthcare Providers & Services industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Renalytix and its competitors. Renalytix's current Institutional Ownership is 0.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renalytix stock overvalued right now?
Renalytix (RNLXD) has a current Institutional Ownership of 0.01%. The stock's GF Value™ is $5.55, compared to a current price of $4.11 — trading 25.9% below its estimated fair value. The current Institutional Ownership is 0.01%. Renalytix's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Renalytix (RNLXD), the current Institutional Ownership is 0.01% as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Renalytix (RNLXD) Overvalued in 2026?

Based on GuruFocus' analysis, Renalytix stock appears to be undervalued. The current stock price of $4.11 is trading 25.9% below its estimated GF Value™ of $5.55.

Key valuation signals for RNLXD:

  • Institutional Ownership: 0.01%
  • GF Value™: $5.55 vs. price of $4.11 (25.9% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the RNLXD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Renalytix Business Description

Other Exchanges RENXF:USARENX:UK2O9:Germany
Address 2 Leman Street, London, GBR, E1W 9US
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
46GF Score

Get the complete analysis for RNLXD

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.11
Price
$5.55
GF Value